ObjectiveTo summarize current patient-derived organoids as preclinical cancer models, and its potential clinical application prospects.
MethodsCurrent patient-derived organoids as preclinical cancer models were reviewed according to the results searched from PubMed database. In addition, how cancer-derived human tumor organoids of pancreatic cancer could facilitate the precision cancer medicine were discussed.
ResultsThe cancer-derived human tumor organoids show great promise as a tool for precision medicine of pancreatic cancer, with potential applications for oncogene modeling, gene discovery and chemosensitivity studies.
ConclusionThe cancer-derived human tumor organoids can be used as a tool for precision medicine of pancreatic cancer.
